Myo-inositol During Pregnancy to Prevent Gestational Diabetes
NCT ID: NCT06575868
Last Updated: 2025-04-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-03-01
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myo-inositol in Obese Pregnant Women
NCT01047982
Gestational Diabetes
COMPLETED
NA
Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes Diet Treated
NCT03763669
Gestational Diabetes
COMPLETED
NA
Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome
NCT03201601
Polycystic Ovarian Syndrome
Infertility
COMPLETED
PHASE2/PHASE3
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
NCT07058675
PCOS
COMPLETED
NA
Treatment of Menstrual Cycle Alterations in Adolescents
NCT06800170
Amenorrhea
Oligomenorrhea
PCOS (Polycystic Ovary Syndrome)
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pregnancy Related
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myo-inositol
Group Type
EXPERIMENTAL
Myo-inositol
Intervention Type
DIETARY_SUPPLEMENT
Patients would begin taking myoinositol upon recruitment
Placebo myo-inositol
Group Type
PLACEBO_COMPARATOR
Myo-inositol placebo
Intervention Type
DIETARY_SUPPLEMENT
Patients would begin taking placebo upon recruitment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myo-inositol
Patients would begin taking myoinositol upon recruitment
Intervention Type
DIETARY_SUPPLEMENT
Myo-inositol placebo
Patients would begin taking placebo upon recruitment
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Singleton gestations
Women aged \> 18 years and \< 45 years
Recruited before 16 weeks gestation
Obese (pre-pregnancy BMI ≥ 30)
Receiving prenatal care at Tufts Medical Center
Planning to give birth at Tufts Medical Center
Can tolerate glucose tolerance test
Willing and able to wear CGM
Willing and able to sign informed consent
Women aged \> 18 years and \< 45 years
Recruited before 16 weeks gestation
Obese (pre-pregnancy BMI ≥ 30)
Receiving prenatal care at Tufts Medical Center
Planning to give birth at Tufts Medical Center
Can tolerate glucose tolerance test
Willing and able to wear CGM
Willing and able to sign informed consent
Exclusion Criteria
Multiple gestation
Preexisting diabetes
Taking medications that impact body weight or metabolism (eg metformin)
Inability to tolerate glucose tolerance test
Adults unable to consent (cognitively impaired adults)
Wards of the state
Non-viable neonates
Neonates of uncertain viability
Preexisting diabetes
Taking medications that impact body weight or metabolism (eg metformin)
Inability to tolerate glucose tolerance test
Adults unable to consent (cognitively impaired adults)
Wards of the state
Non-viable neonates
Neonates of uncertain viability
Minimum Eligible Age
18 Years
Maximum Eligible Age
45 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tufts Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tufts Medical Center
Boston, Massachusetts, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Muller G, Wied S, Crecelius A, Kessler A, Eckel J. Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms. Endocrinology. 1997 Aug;138(8):3459-75. doi: 10.1210/endo.138.8.5308.
Reference Type
BACKGROUND
Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811-27. doi: 10.1016/j.biochi.2013.05.011. Epub 2013 Jun 10.
Reference Type
BACKGROUND
Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013 Apr;29(4):375-9. doi: 10.3109/09513590.2012.743020. Epub 2013 Jan 22.
Reference Type
BACKGROUND
Scioscia M, Kunjara S, Gumaa K, Gomez Galan AM, McLean P, Rodeck CH, Rademacher TW. Altered urinary release of inositol phosphoglycan A-type in women with gestational diabetes mellitus. Gynecol Obstet Invest. 2007;64(4):217-23. doi: 10.1159/000106494. Epub 2007 Jul 30.
Reference Type
BACKGROUND
Malvasi A, Casciaro F, Minervini MM, Kosmas I, Mynbaev OA, Pacella E, Monti Condesnitt V, Creanza A, Di Renzo GC, Tinelli A. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18(2):270-4.
Reference Type
BACKGROUND
Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972-5. doi: 10.1111/j.1464-5491.2011.03284.x.
Reference Type
BACKGROUND
D'Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, Petrella E, Neri I, Pintaudi B, Corrado F, Facchinetti F. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. Obstet Gynecol. 2015 Aug;126(2):310-315. doi: 10.1097/AOG.0000000000000958.
Reference Type
BACKGROUND
Fraticelli F, Celentano C, Zecca IA, Di Vieste G, Pintaudi B, Liberati M, Franzago M, Di Nicola M, Vitacolonna E. Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. Acta Diabetol. 2018 Aug;55(8):805-812. doi: 10.1007/s00592-018-1157-4. Epub 2018 May 17.
Reference Type
BACKGROUND
D'Anna R, Corrado F, Loddo S, Gullo G, Giunta L, Di Benedetto A. Myoinositol plus alpha-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study. Sci Rep. 2021 Apr 23;11(1):8866. doi: 10.1038/s41598-021-88329-x.
Reference Type
BACKGROUND
Vitale SG, Corrado F, Caruso S, Di Benedetto A, Giunta L, Cianci A, D'Anna R. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial. Int J Food Sci Nutr. 2021 Aug;72(5):670-679. doi: 10.1080/09637486.2020.1852191. Epub 2020 Nov 25.
Reference Type
BACKGROUND
Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care. 2017 Jun;40(6):759-763. doi: 10.2337/dc16-2449. Epub 2017 Mar 21.
Reference Type
BACKGROUND
Kulshrestha V, Balani S, Kachhawa G, Vanamail P, Kumari R, Sharma JB, Bhatla N. Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2021 May;260:42-47. doi: 10.1016/j.ejogrb.2021.02.017. Epub 2021 Feb 19.
Reference Type
BACKGROUND
Amaefule CE, Drymoussi Z, Gonzalez Carreras FJ, Pardo Llorente MDC, Lanz D, Dodds J, Sweeney L, Pizzo E, Thomas A, Heighway J, Daru J, Sobhy S, Poston L, Khalil A, Myers J, Harden A, Hitman G, Khan KS, Zamora J, Perez T, Huda MSB, Thangaratinam S. Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study. BMJ Open. 2022 Mar 11;12(3):e050110. doi: 10.1136/bmjopen-2021-050110.
Reference Type
BACKGROUND
Horgan R, Hage Diab Y, Fishel Bartal M, Sibai BM, Saade G. Continuous Glucose Monitoring in Pregnancy. Obstet Gynecol. 2024 Feb 1;143(2):195-203. doi: 10.1097/AOG.0000000000005374. Epub 2023 Sep 28.
Reference Type
BACKGROUND
Garcia-Moreno RM, Benitez-Valderrama P, Barquiel B, Gonzalez Perez-de-Villar N, Hillman N, Lora Pablos D, Herranz L. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022 Jan;39(1):e14703. doi: 10.1111/dme.14703. Epub 2021 Oct 13.
Reference Type
BACKGROUND
Santamaria A, Di Benedetto A, Petrella E, Pintaudi B, Corrado F, D'Anna R, Neri I, Facchinetti F. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med. 2016 Oct;29(19):3234-7. doi: 10.3109/14767058.2015.1121478. Epub 2015 Dec 23.
Reference Type
BACKGROUND
Pintaudi B, Di Vieste G, Corrado F, Lucisano G, Giunta L, D'Anna R, Di Benedetto A. Effects of myo-inositol on glucose variability in women with gestational diabetes. Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6567-6572. doi: 10.26355/eurrev_201810_16073.
Reference Type
BACKGROUND
D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013 Apr;36(4):854-7. doi: 10.2337/dc12-1371. Epub 2013 Jan 22.
Reference Type
BACKGROUND
Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2024 Jan 1;47(1):26-43. doi: 10.2337/dci23-0085.
Reference Type
BACKGROUND
Baptiste-Roberts K, Nicholson WK, Wang NY, Brancati FL. Gestational diabetes and subsequent growth patterns of offspring: the National Collaborative Perinatal Project. Matern Child Health J. 2012 Jan;16(1):125-32. doi: 10.1007/s10995-011-0756-2.
Reference Type
BACKGROUND
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.
Reference Type
BACKGROUND
D'Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto A. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012 Jun;28(6):440-2. doi: 10.3109/09513590.2011.633665. Epub 2011 Nov 28.
Reference Type
BACKGROUND
Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509-15. doi: 10.3109/09513590.2011.650660. Epub 2012 Feb 1.
Reference Type
BACKGROUND
Matarrelli B, Vitacolonna E, D'Angelo M, Pavone G, Mattei PA, Liberati M, Celentano C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013 Jul;26(10):967-72. doi: 10.3109/14767058.2013.766691. Epub 2013 Mar 1.
Reference Type
BACKGROUND
Celentano C, Matarrelli B, Pavone G, Vitacolonna E, Mattei PA, Berghella V, Liberati M. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. J Matern Fetal Neonatal Med. 2020 Mar;33(5):743-751. doi: 10.1080/14767058.2018.1500545. Epub 2018 Dec 17.
Reference Type
BACKGROUND
Esmaeilzadeh S, Ghadimi R, Mashayekh-Amiri S, Delavar MA, Basirat Z. The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. Minerva Obstet Gynecol. 2023 Aug;75(4):357-364. doi: 10.23736/S2724-606X.22.05036-9. Epub 2022 Jun 8.
Reference Type
BACKGROUND
Castorino K, Polsky S, O'Malley G, Levister C, Nelson K, Farfan C, Brackett S, Puhr S, Levy CJ. Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2020 Dec;22(12):943-947. doi: 10.1089/dia.2020.0085.
Reference Type
BACKGROUND
Motuhifonua SK, Lin L, Alsweiler J, Crawford TJ, Crowther CA. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2023 Feb 15;2(2):CD011507. doi: 10.1002/14651858.CD011507.pub3.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00005304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Women With Hyperandrogenic PCOS With Two Different Ratios of Myo-inositol:D-chiro-inositol: A Comparison
NCT06715527
COMPLETED
NA
MYPP-trial: Myo-inositol Supplementation to Prevent Pregnancy Complications in Women With Polycystic Ovary Syndrome.
NCT05524259
UNKNOWN
NA
Effects of Myo-inositol in Women With Polycystic Ovary Syndrome
NCT04892186
COMPLETED
NA
Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women
NCT03585738
NOT_YET_RECRUITING
NA
Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters
NCT01514942
COMPLETED
PHASE4
Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
NCT03767569
UNKNOWN
PHASE3
Evaluating the Effect of Inositol Supplementation in Overweight Children on Basal Insulin and Body Weight
NCT03920787
UNKNOWN
NA
Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
NCT02086526
COMPLETED
PHASE1
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
NCT01070160
COMPLETED
Comparison of Myoinositol and Metformin in PCO
NCT04204044
UNKNOWN
EARLY_PHASE1
Impact of Myo-Inositol Alone vs Myo-Inositol Plus Metformin on Conception, Adherence, and Tolerability in PCOS
NCT07323589
COMPLETED
PHASE3
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
NCT03059173
RECRUITING
PHASE3
Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
NCT04867252
COMPLETED
PHASE2
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
NCT00868140
TERMINATED
NA
Myoinositol Treatment and Asprosin Levels in PCOS
NCT05951309
COMPLETED
NA
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03177122
UNKNOWN
PHASE4
Inositol Treatment in Different Type of PCOS Phenotype
NCT05678114
COMPLETED
NA
Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients
NCT01246310
TERMINATED
NA
Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients
NCT02562664
COMPLETED
PHASE2
Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)
NCT00682890
TERMINATED
PHASE4
Myo-inositol, D-chiro-inositol and Glucomannan in PCOS
NCT03608813
COMPLETED
Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome
NCT00670800
COMPLETED
NA
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone
NCT01555190
COMPLETED
NA
Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome
NCT02802215
UNKNOWN
PHASE2/PHASE3